Results 81 to 90 of about 1,341 (168)

Teprotumumab in Thyroid-Associated Ophthalmopathy: Rationale for Therapeutic Insulin-Like Growth Factor-I Receptor Inhibition

, 2020
Thyroid-associated ophthalmopathy (TAO) is an autoimmune component of Graves\u27 disease for which no currently available medical therapy provides reliable and safe benefit.
Terry J. Smith
core  

Immune checkpoints: new insights into the pathogenesis of thyroid eye disease

Frontiers in Immunology
Thyroid eye disease (TED) is a disfiguring autoimmune disease characterized by changes in the orbital tissues and is caused by abnormal thyroid function or thyroid-related antibodies. It is the ocular manifestation of Graves’ disease.
Xingyi Shu, Yuchao Shao, Yuqing Chen, Chengcheng Zeng, Xiao Huang, Ruili Wei   +5 more
doaj   +1 more source

Teprotumumab and Tocilizumab in the Therapy of Thyroid Eye Disease.

Gegenstand: Die vorliegende Bachelorarbeit befasst sich mit dem Krankheitsbild der Endokrinen Orbitopathie (EO) sowie dem Vergleich der Medikamente Tocilizumab und Teprotumumab hinsichtlich ihrer Wirksamkeit in der Behandlung der EO.
Ahmed, Narin
core   +1 more source

Thyroid Eye Disease: How A Novel Therapy May Change The Treatment Paradigm

Therapeutics and Clinical Risk Management, 2019
Yao Wang,1 Amy Patel,1 Raymond S Douglas1,2 1Department of Surgery, Division of Ophthalmology, Cedars Sinai Medical Center, Los Angeles, CA, USA; 2State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou ...
Wang Y, Patel A, Douglas RS
doaj  

Teprotumumab Induced Adrenal Insufficiency: A Case Report

We report a case of adrenal insufficiency in a patient who had been receiving teprotumumab infusions for the treatment of thyroid eye disease.
Justin Youn; Douglas Van Putten; Eman Hawy
core  

The therapeutic revolution in thyroid eye disease: from orbital radiotherapy to teprotumumab and AI

Frontiers in Medicine
Thyroid eye disease (TED) is a vision-threatening and quality-of-life-impairing manifestation of autoimmune thyroid disease, driven by orbital fibroblast activation, inflammation, and tissue remodeling.
XiaoLi Yuan, Han Li, Feng Wang
doaj   +1 more source

Teprotumumab Efficacy in Retreatment and Longer-Term Thyroid Eye Disease: OPTIC-X Study Results

, 2021
Teprotumumab, an insulin-like growth factor I receptor inhibitory antibody, improves proptosis, diplopia, inflammatory signs/symptoms, and quality of life in thyroid eye disease (TED) patients.1,2 In the phase 3, randomized, placebo-controlled trial ...
Raymond S, Douglas; Saba Sile; Terry J. Smith; George J. Kahaly
core  

Linsitinib inhibits proliferation and induces apoptosis of both IGF-1R and TSH-R expressing cells

Frontiers in Immunology
BackgroundThe insulin-like growth factor 1 receptor (IGF-1R) and the thyrotropin receptor (TSH-R) are expressed on orbital cells and thyrocytes. These receptors are targeted in autoimmune-induced thyroid eye disease (TED). Effective therapeutic treatment
Maximilian Luffy, Anna-Lena Ganz, Stefanie Wagner, Jan Wolf, Julian Ropertz, Ryan Zeidan, Jeffrey D. Kent, Raymond S. Douglas, George J. Kahaly   +8 more
doaj   +1 more source

Teprotumumab (Tepezza)-Related Hyperglycemia is Associated With Baseline Glycemic Status in Thyroid Eye Disease

Teprotumumab (Tepezza) is an insulin-like growth factor 1 receptor antagonist that was recently approved for the treatment of Thyroid Eye Disease (TED), a potentially sight-threatening and debilitating orbital inflammatory disease.
Tracy Lang; Aaron Rael; Kristen Park; Jessica Chang; Sandy Zhang-Nunes
core  

Assessment of Ocular Misalignment Before and After Teprotumumab Therapy in Patients With Thyroid Orbitopathy

, 2022
Diplopia due to thyroid orbitopathy can be disabling with limited management options that include prisms or strabismus surgery. Teprotumumab, an insulin like growth factor one (IGF-1) antagonist, reduces proptosis and improves double vision. Two clinical
Alexander M. Solomon; Gibran Merchant; Madhura Tamhankar
core